Nobelpharma America Presents Findings from Natural History Database of the TSC Alliance on the Characterization of Facial Angiofibroma and the Use of Topical Rapamycin in People with Tuberous Sclerosis Complex in the US at the 30th Annual Masters of Pediatric Dermatology Conference
09 Aug 2022
Nobelpharma Will Also Have an Exhibit at the Conference
BETHESDA, Md., Aug. 9, 2022 /PRNewswire/ -- Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, today announced that data from a scientific poster on a survey of caregivers and individuals with tuberous sclerosis complex (TSC) will be presented at the Masters of Pediatric Dermatology Conference August 11-12, 2022 in Miami, Florida. In addition to the scientific poster, the company will have Nobelpharma exhibit space at the meeting.
"Characterization of facial angiofibroma and understanding its management in the US may help to provide meaningful treatment options and support for this rare disease," said Yoshiki Kida, President and CEO of Nobelpharma America. "We are excited to share this data from the Natural History database with the clinicians who are often on the front lines of caring for people who live with TSC."
Details of Poster Presentation:
Title: Factors Associated with Facial Angiofibroma Related to Tuberous Sclerosis Complex and use of Topical mTOR InhibitormTOR Inhibitor in the United States: A Retrospective Analysis of the Natural History Database
Presenter: Sreedevi Boggarapu, PhD, CMPP, Director, Scientific Publications at Nobelpharma America, or a Medical Affairs colleague will be onsite during official breaks:
Thursday, August 11th
9:30am-10:00am
11:30am – 12:00pm
12:45pm-1:15pm
3:00pm – 3:30pm
Friday, August 12th
9:00am – 9:15am
11:30am – 12:00pm
12:45pm – 1:15pm
2:45pm – 3:00pm
Nobelpharma will also have exhibit space at the Masters of Pediatric Dermatology Conference, where the company will display medical information on facial angiofibroma due to TSC. For more information and to register for the 30th Annual Masters of Pediatric Dermatology Conference, visit https://www.livderm.org/masters-of-pediatric-dermatology-2022/.
TSC is a rare genetic disease that affects approximately one in 6,000 live births. Nearly one million people worldwide are estimated to have TSC, with approximately 50,000 in the United States. TSC causes non-cancerous tumors, or hamartomas, to form in vital organs including the skin. TSC may also cause facial angiofibromas, which are pink or red bumps usually located on the cheeks, nose, and chin that may cause bleeding, itching, redness, and significant disfiguration without treatment. Many individuals with TSC also present with autism, epilepsy, and other neuropsychiatric disorders.
About Nobelpharma America
Nobelpharma America, LLC (NPA) is focused on the commercialization of pharmaceuticals and medical devices that expand treatment options for people with rare diseases. In 2019, NPA became the first wholly owned global subsidiary of Nobelpharma Co., Ltd., which is based in Tokyo. The company, which is named after Alfred Nobel, remains committed to honoring his innovative and scientific legacy by developing treatments for diseases that often go overlooked because of the small number of individuals affected. For more information visit nobelpharma-us.com.
SOURCE Nobelpharma America
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.